Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 in pulmonary fibrosis
NCT04308681Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of admilparant in idiopathic pulmonary fibrosis (IPF), progressive fibrotic interstitial lung disease (PF-ILD), sponsored by Bristol Myers Squibb. Started Jul 2020; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)progressive fibrotic interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT04308681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308681.